The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels

Atherosclerosis

Volumn 152, Issue 2, 2000, Pages 519-526

  Kroon, Abraham A ^a   Van't Hof, Martin A ^a   Demacker, Pierre N M ^a   Stalenhoef, Anton F H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Lathosterol; LDL apheresis; Lipid lowering; Rebound; Sitosterol

Indexed keywords

APOLIPOPROTEIN B; LATHOSTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; SITOSTEROL;

APHERESIS; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; HUMAN; HYPERCHOLESTEROLEMIA; KINETICS; PRIORITY JOURNAL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; BLOOD COMPONENT REMOVAL; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEIN(A); LIPOPROTEINS, LDL; MALE; MIDDLE AGED; SIMVASTATIN; SITOSTEROLS; TRIGLYCERIDES;

EID: 0033811877     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00371-3     Document Type: Article

References (52)

1. Keller C. LDL-apheresis: results of long-term treatment and vascular outcome. Atherosclerosis. 86:1991;1-8.
2. Agishi T., Wood W., Gordon B. LDL-apheresis using the Liposorber® LA-15 system in coronary and peripheral vascular disease associated with severe hypercholesterolemia. Curr. Ther. Res. 55:1994;879-904.
3. Koga N., Iwata Y. Pathological and angiographic regression of coronary atherosclerosis by LDL-apheresis in a patient with familial hypercholesterolemia. Atherosclerosis. 90:1991;9-21.
4. Yamamoto A. Regression of atherosclerosis in humans by lowering serum cholesterol. Atherosclerosis. 89:1991;1-10.
5. Tait G.W., Packard C.J., Sheperd J., Hutton I., Lorimer R.A. Cholesterol reduction and regression of coronary atherosclerosis: The Coronary Atheroma Regression Study. Gordon B.R., Gotto Jr A.M. The Treatment of Severe Hypercholesterolemia: Can We Impact Disease Course? 1992;80-89 Exerpta Medica, Princeton, NJ.
6. Tatami R., Inoue N., Itoh H., et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. Atherosclerosis. 95:1992;1-13.
7. Borberg H., Oette K. Experience with and conclusions from three different trials on low density lipoprotein apheresis. Agishi T., Kawamura A., Mineshima M. Therapeutic Plasmapheresis (XII). 1993;13-20 VSP, Utrecht, The Netherlands.
8. Schuff-Werner P., Gohlke H., Bartmann U., et al. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur. J. Clin. Invest. 24:1994;724-732.
9. Daida H., Lee Y.L., Yokoi H., et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein(a) levels with Low-density lipoprotein apheresis. Am. J. Cardiol. 73:1994;1037-1040.
10. Thompson G.R., Maher W.M.G., Matthews S., et al. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 345:1995;811-816.
11. Kroon A.A., Aengevaeren W.R.M., van der Werf T., et al. The LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 93:1996;1826-1835.
12. Park J.W., Merz M., Braun P. Effect of HELP-LDL-apheresis on outcomes in patients with advanced coronary atherosclerosis and severe hypercholesterolemia. Atherosclerosis. 139:1998;401-409.
13. Koga N., Watanabe K., Kurashige Y., Sato T., Hiroki T. Long-term effects of LDL-apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients. J. Intern. Med. 246:1999;35-43.
14. Kroon A.A., van Asten W.N.J.C., Stalenhoef A.F.H. The LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on peripheral vascular disease. Ann. Intern. Med. 125:1996;945-954.
15. Mol M.J.T.M., Stalenhoef A.F.H. Homozygous familial hypercholesterolemia: metabolic studies and treatment with LDL-apheresis. Neth. J. Med. 36:1990;279-287.
16. Apstein C.S., Zilversmith D.B., Lees R.S., George P.K. Effect of intensive plasmapheresis on the plasma cholesterol concentration with familial hypercholesterolemia. Atherosclerosis. 31:1978;105-115.
17. Schwartzkopff W., Nold A., Gräfenhahn H., von Baeyer H., Schwerdtfeger R. Efficacy of plasmapheresis cascade-filtration and dextran-sulfate adsorption apheresis with calculation of the recovery rate of lipids and lipoproteins. Contrib. Infus. Ther. 23:1988;103-111.
18. Bosch T., Seidel D., Gurland H.J. Efficacy of lipid apheresis: definitions and influencing factors. Int. J. Artif. Organs. 18:1995;210-215.
19. Parker T.S. Low-density lipoprotein apheresis. Selective removal of apolipoprotein B-containing lipoproteins in patients with familial hypercholesterolemia. Gordon B.R., Gotto Jr A.M. Treatment of Severe Hypercholesterolemia: Can We Impact Disease Course? 1992;31-42 Excerpta Medica, Princeton, NJ.
20. Pfohl M., Naoumova R.P., Klass C., et al. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J. Lipid Res. 35:1994;1946-1955.
21. Thompson G.R. Plasma exchange for hypercholesterolemia. Lancet. i:1981;1246-1248.
22. Thompson G.R., Myant N.B. Low density lipoprotein turnover in familial hypercholesterolaemia after plasma exchange. Atherosclerosis. 23:1976;371-377.
23. Thompson G.R., Spinks T., Ranicar A., Myant N.B. Non-steady-state studies of low-density lipoprotein turnover in familiar hypercholesterolemia. Clin. Sci. Mol. Med. 52:1977;361-369.
24. Soutar A.K., Myant N.B., Thompson G.R. Metabolism of apolipoprotein B-containing lipoproteins in familial hypercholesterolaemia. Effects of plasma exchange. Atherosclerosis. 32:1979;315-325.
25. Gylling H., Kauppinen-Makelin R., Koivisto V., Taskinen M.-R., Miettinen T.A. LDL-cholesterol concentration and cholesterol absorption and metabolism during two years' treatment with LDL-apheresis in familial hypercholesterolemia. Eur. Heart. J. 14:(suppl. A):1993;56. (abstract).
26. 13C]leucine infusion in normal volunteers. Eur. J. Clin. Invest. 23:1993;602-614.
27. Mabuchi H., Michishita I., Takeda M., Fujita H. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis. 68:1987;19-25.
28. Aengevaeren W.R.M., Kroon A.A., Stalenhoef A.F.H., Uijen G.J.H., van der Werf T. Low density lipoprotein-apheresis improves regional myocardial blood flow in patients with hypercholesterolemia and extensive coronary artery disease. The LDL-Apheresis Atherosclerosis Regression Study (LAARS). J. Am. Coll. Cardiol. 28:1996;1696-1704.
29. Miettinen T.A. Diurnal variation of cholesterol precursors squalene and methylsterols in human plasma lipoproteins. J. Lipid Res. 23:1982;466-473.
30. Kempen H.J.M., Glatz J.F.C., Gevers-Leuven J.A., van der Voort H.A., Katan M.B. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J. Lipid Res. 29:1988;1149-1155.
31. Kempen H.J.M., Gevers-Leuven J.A., van der Voort H.A., de Knijff P., Havokes L. Lathosterol level in plasma is elevated in type III hyperlipoproteinemia, but not in non-type III subjects with apolipoprotein E2/E2 phenotype, nor in type IIa or IIb hyperlipoproteinemia. Metabolism. 40:1991;231-235.
32. Björkhem I., Miettinen T.A., Réihner E., Ewerth S., Angelin B., Einarson K. Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver. J. Lipid Res. 28:1987;1137-1143.
33. Strandberg T.E., Tilvis R.S., Miettinen T.A. Metabolic variables of cholesterol during squalene feeding in humans: comparison with cholestyramine treatment. J. Lipid Res. 31:1990;1637-1643.
34. Réihner E., Rudling M., Stahlberg D., et al. Influence of pravastatin, a specific inhibitor of HMG CoA reductase, on hepatic metabolism of cholesterol. N. Engl. J. Med. 323:1990;224-228.
35. Tilvis R.S., Miettinen T.A. Serum plant sterols and their relation to cholesterol absorption. J. Clin. Nutr. 43:1986;92-97.
36. Miettinen T.A., Tilvis R.S., Kesäniemi Y.A. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am. J. Epidemiol. 131:1990;20-31.
37. Demacker P.N.M., Hijmans A.G., Vos-Jansen H.E., van't Laar A., Jansen A.P. A study of the use of polyethylene glycol in estimating cholesterol in high-density lipoprotein. Clin. Chem. 26:1980;1775-1779.
38. Lopes-Virella M.F., Virella G., Evans G., Malenkos S.B., Colwell J.A. Immunonephelometric assay of human apolipoprotein AI. Clin. Chem. 26:1980;1205-1208.
39. Kroon A.A., van't Hof M.A., Stalenhoef A.F.H. Assessment of time-averaged levels in treatment of hypercholesterolemia by LDL-apheresis (LA). Neth. J. Med. 40:1992;A50-A51. (abstract).
40. Goodman D.S., Noble R.O., Dell R.B. Three-pool model of the long-term turnover of plasma cholesterol in man. J. Lipid Res. 14:1973;178-188.
41. Parhofer K.G., Hugh P., Barrett P.H.R., Bier D.M., Schonfeld G. Determination of kinetic parameters of apolipoprotein B metabolism using amino acids labelled with stable isotopes. J. Lipid Res. 32:1991;1311-1323.
42. Eriksson M., Berglund L., Gabrielsson J., Lantz B., Angelin B. Non-steady-state kinetics of low density lipoproteins in man: studies after plasma exchange in healthy subjects and patients with familial hypercholesterolaemia. Eur. J. Clin. Invest. 23:1993;746-752.
43. Havel R.J. Origin, metabolic fate and metabolic function of plasma lipoproteins. Steinberg D., Olefsky J.M. Contemporary issues in endocrinology and metabolism. 1986;117-141 Churchill Livingstone, New York.
44. Sigurdsson G., Nicoll A., Lewis B. Conversion of very low density lipoprotein to low density lipoprotein. A metabolic study of apolipoprotein B kinetics in human subjects. J. Clin. Invest. 56:1975;1481-1490.
45. Armstrong V.W., Schleef J., Thiery J., Muche R., Schuff-Werner P. Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels. Eur. J. Clin. Invest. 19:1989;235-240.
46. Gylling H., Vanhanen H., Miettinen T.A. Effects of ketoconazole on cholesterol precursors and low density lipoprotein kinetics in hypercholesterolemia. J. Lipid Res. 34:1993;59-67.
47. Koizumi J., Koizumi I., Uno Y., et al. Reduction of lipoprotein(a) by LDL-apheresis using dextran sulfate cellulose column in patients with familial hypercholesterolemia. Atherosclerosis. 100:1993;65-74.
48. Feillet C., Cristol J.P., Michel F., et al. Cholesterol biosynthesis in normocholesterolemic patients after cholesterol removal by plasmapheresis. J. Clin. Apheresis. 12:1997;110-115.
49. Pfohl M., Naoumova R.P., Neuwirth C., et al. Upregulation of cholesterol synthesis after acute reduction of low density lipoprotein by apheresis in normocholesterolaemic subjects: evidence for a threshold effect. Atherosclerosis. 135:1997;257-262.
50. Kempen H.J.M., de Knijff P., Boomsma D.I., van der Voort H.A., Gevers Leuven J.A., Havekes L. Plasma levels of lathosterol and phytosterols in relation to age, sex, anthropometric parameters, plasma lipids, and apolipoprotein E phenotype, in 160 Dutch families. Metabolism. 40:1991;604-611.
51. Goldberg I.J., Holleran S., Ramakrishnan R., et al. Lack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolism. J. Clin. Invest. 86:1990;801-808.
52. Uusitupa M.I., Miettinen T.A., Happonen P., et al. Lathosterol and other noncholesterol sterols during treatment of hypercholesterolemia with lovastatin alone and with cholestyramine or guar gum. Arterioscler. Thromb. 12:1992;807-813.